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estimates of 1:2 500 to 1:5 000, its true prevalence is unknown, as 
some affected individuals may remain asymptomatic and others may be 
misdiagnosed. The importance of this unusual heart muscle disease is in 
its role as a major cause of sudden cardiac death in the young, especially 
athletes.(1,2,3,19) 
PATHOGENESIS
ARVC is familial in up to 50% of cases, with an autosomal dominant 
pattern of inheritance occurring in the majority. Rarer recessive modes 
of inheritance, however, do occur. One of these may be associated with 
abnormalities of skin (palmoplantar hyperkeratosis) and hair (wooly 
hair): the so-called Naxos disease.(4,6,19)
The causative genes encode proteins of cell junctions (plakoglobin, 
plakophilin, desmoglein, desmocollin, desmoplakin), which mediate cell-
cell interaction, allowing for both mechanical and electrical coupling of 
adjacent cells. Mechanical coupling is important for providing structural 
integrity and allowing synchronous contraction of myocardium, while 
electrical coupling, via gap junctions, allows for rapid spread of 
depolarizing electrical waves.(4,6,19) 
Mutations may lead to remodeling of the intercalated disks of 
cell junctions, resulting in loss of the structural integrity of the 
myocardium and myocyte death, with replacement by fi brosis and 
adipocytes. This dystrophy of the right ventricular myocardium with 
fi bro-fatty replacement, which is the pathological hallmark of ARVC, 
serves as substrate for the development of life-threatening arrhythmias 
(Figure 1). (4,6,19)
Since heritable penetrance of ARVC is incomplete and genetic 
mutations within families have been shown to display variable pheno-
typic expression, both environmental factors and other genetic 
modifi ers have been implicated in its pathogenesis. Endurance sport 
and intense or prolonged physical activity have been consistently shown, 
in both humans and animal models of ARVC, to be a major modifi er in 
terms of frequency and severity of symptoms, as well an increased risk 
of death. Endurance sport in ARVC is associated with a 5-fold increase 
in the risk of sudden death in the young. (6,16,19)
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 Arrhythmogenic Right Ventricular Car-
diomyopathy (ARVC), commonly an inherited condition 
affecting cell junctions, may present with sudden death 
or life-threatening arrhythmias. The pathogenesis, clinical 
presentation, diagnostic evaluation and treatment are 
reviewed.  The South African ARVC Registry is described, 
giving the aims, organization and missions which include: 
establishment of a DNA/tissue bank, epidemiology, risk 
assessment and evaluation of therapy, imaging, pathological 
diagnosis and diagnostic validation. Results of analysis of 
the fi rst 80 confi rmed cases enrolled in the registry confi rm 
its familial occurrence, high mortality and involvement of 
the left ventricle. A common fi nding is participation in 
sport. A new mutation has been discovered affecting the 
plakophyllin gene.  Physicians are invited to refer patients 
with confi rmed or suspected ARVC for inclusion in the 
Registry. SAHeart 2008; 5:148-154
ABSTRACT
BACKGROUND
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a 
progressive disorder of the right ventricular myocardium, associated 
with ventricular arrhythmias, sudden death and heart failure. Despite 
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CLINICAL
The clinical picture is often described in four ‘‘classical’’ phases:(5)
1.  The concealed phase, with either subtle or no structural changes, 
occurs in affected individuals, who despite being asymptomatic, 
remain at risk of sudden cardiac death (SCD) from an arrhythmia 
during episodes of extreme exertion. These individuals may be 
identifi ed through family screening; however, in a signifi cant pro-
portion the diagnosis is fi rst established at postmortem examination, 
the initial presentation having been SCD.
2.  The overt electrical phase is characterized by effort-induced 
palpitations and syncope. The symptoms are due to ventricular 
arrhythmias of right ventricular (RV) origin, manifesting as multiple 
ventricular ectopic beats, sustained and non-sustained ventricular 
tachycardia (VT) with left bundle branch block (LBBB) morphology. 
Morphological and functional cardiac abnormalities are usually 
present at this stage, but often overlooked.
3.  Diffuse right ventricular dysfunction occurs as a result of progressive 
loss of RV myocardium presenting with severe right-sided heart 
failure, with relatively preserved left ventricular function.
4.  Biventricular failure or dilated cardiomyopathy phase in which both 
ventricles are equally affected; ARVC mimicking dilated cardiomyo-
pathy. This may be severe enough to require cardiac transplantation.
DIAGNOSTIC EVALUATION
A clinical diagnosis is achieved by demonstrating functional and 
structural alterations of the right ventricle, coupled with depolarization 
and repolarization abnormalities, arrhythmias with LBBB morphology 
(Figure 2) and fi bro-fatty replacement on histology (Figure 1). ARVC 
is confi rmed by a combination of 2 major, 1 major and 2 minor, or 4 
minor criteria (Table 1).(4) The main differential diagnoses include 
idiopathic right ventricular outfl ow tract tachycardia, myocarditis, dilated 
cardiomyopathy and sarcoidosis.(4,5,19)
An ECG is essential in the evaluation of ARVC, providing both diagnostic 
and prognostic information. Abnormalities on ECG are detected in 
up to 90% of ARVC cases. Features include the presence of diffuse 
precordial T-wave inversions (beyond V2), an Epsilon wave in V1, 
widened localized QRS complex in leads V1-V3 (parietal block) and 
prolonged S-wave upstroke (≥ 55 ms) in V1-V3 (Figure 3).(8,9,19
T-wave inversion in leads V1-V3 in the absence of RBBB and coronary 
disease is a well-established electrocardiographic feature of ARVC and 
is a minor criterion (Table 1). An epsilon wave (defi ned as a discrete 
wave following the QRS complex in V1-V3) and parietal block are both 
major diagnostic criteria (Table 1). Late action potentials on signal 
averaged electrocardiogram (SAECG) recordings are the counterpart 
of the epsilon waves, demonstrating the presence of areas of slow 
conduction and late depolarization,  and predict inducibility of ventricular 
tachycardia (VT) on electrophysiological study (EPS), as well as 
implantable cardioverter defi brillator (ICD) therapies.(17,19) Prolonged 
FIGURE 1: Typical histological features of ARVC
A: This section of the right ventricular free wall from an explanted heart shows extensive fi bro-fatty 
replacement of the myocardium that is almost transmural, reaching to the endocardial surface at the bottom 
of the picture.
B: At higher magnifi cation, abnormal isolated atrophic myocytes with 
dysmorphic bizarre nuclei surrounded by fi bro-fatty tissue can be seen.
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S-wave upstroke in V1-V3, the most prevalent electrocardiographic 
feature, is seen in 95% of the patients. It correlates with disease severity 
and the induction of ventricular tachycardia at EPS.(9,19)
EPS should be considered in all individuals where ARVC is suspected or 
confi rmed, as it has important diagnostic, prognostic and therapeutic 
utility. Inducibility of VT during EPS, correlates with prognosis, 
identifying individuals for ICD and/or radiofrequency ablation.(4,14,15,19) 
Electroanatomic voltage mapping is able to detect areas of low voltage 
corresponding to myocardial atrophy with fi bro-fatty replacement, 
enabling distinction between ARVC and idiopathic right ventricular 
outfl ow tract tachycardia.  As the disease process is patchy, this mapping 
also allows for more directed targeting of endomyocardial biopsy.(18,19)
RV angiography (RVA) is the imaging gold standard in ARVC and may 
demonstrate the classical features of localized aneurysms, prominent 
trabeculations of the RV and global dilation with decreased ejection 
fraction (Figure 4).(19,21) 
Echocardiography, despite being widely available and frequently 
performed, has a low sensitivity for the detection of ARVC due to the 
diffi culty of imaging the RV. Despite these shortcomings, it remains 
useful as the fi rst-line non-invasive imaging modality in assessing both 
presence of disease at primary evaluation in suspected ARVC and in 
FIGURE 2: An ECG recording of Ventricular Tachycardia (VT) in a patient with ARVC
This ECG shows a sustained wide QRS complex regular tachycardia at a heart rate of 240bpm with a “left bundle branch block-like”  morphology and a QRS axis of 60º.  This VT appears to be 
arising from the RV outfl ow region.  The usual differential diagnosis of the underlying pathophysiology of this VT includes ARVC and the idiopathic RV outfl ow tract VT.
Abbreviations: RV = right ventricle, LV = left ventricle, ARVD = arrhythmogenic right ventricular 
dysplasia, RBBB = right bundle branch block, LBBB = left bundle branch, VT = ventricular 
tachycardia, PVC = premature ventricular complex (Modifi ed from McKenna et al.)(4)
TABLE 1:  Diagnostic Criteria for ARVC
   Category Major Criteria Minor Criteria
Structural or  Functional
abnormalities
Tissue Characterization
ECG Depolarization / 
Conduction abnormalities
ECG Repolarization 
abnormalities
Arrhythmias
Family History
1.  Severe dilatation and 
reduction of RV ejection 
fraction with mild or no 
LV involvement.
2.  Localized RV aneurysms 
(akinetic or dyskinetic 
areas with diastolic 
bulgings). 
3.  Severe segmental 
dilatation of RV.
Fibro-fatty replacement of 
myocardium on histology
1.  Epsilon waves or
2.  Localized prolongation 
(>110 ms) of QRS 
complex in right 
precordial leads (V1-V3).
Familial disease confi rmed 
at autopsy or biopsy.
1.  Mild global RV dilatation 
and/or ejection fraction 
reduction with normal LV.
2.  Mild segmental dilatation 
of RV.
3. Regional RV hypokinesia.
Late potentials on SAECG
Inverted T waves in V1- V3 
(above age 12 yrs, in 
absence of RBBB)
1.  LBBB VT on ECG or 
Holter monitoring or 
during exercise testing.
2.  Frequent PVCs 
(>1000/24 h on Holter)
1.  Family history of 
premature sudden death 
(<35 years of age) due 
to suspected ARVC.
2.  Family history (clinical 
diagnosis based on 
present criteria)
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family screening and also, by means of serial examinations, progression 
during the follow-up of affected patients. Both functional and structural 
abnormalities can be evaluated, the detection of which may avoid the 
need for invasive RVA or costly cardiac magnetic resonance imaging 
(CMRI).(10,19) 
CMRI has become integral to the evaluation of ARVC because it is non-
invasive, with increased sensitivity over echocardiography. Accurate 
measurements of both RV and LV size, volume and ejection fraction are 
obtained. Wall motion abnormalities with akinesia, dyskinesia and 
aneurysms diagnostic of ARVC are readily appreciated, as well as 
evidence of fi brosis and fatty infi ltration (Figure 5). However, the 
contraindication of CMRI in the presence of ICDs, high inter-observer 
variability coupled with a lack of standardized protocols producing 
variable results have resulted in CMRI disappointingly not living up to its 
initial expectations as the defi nitive mode of investigation. This is of 
particular importance in the South African context with its lack of 
expertise in the fi eld of CMRI. In the case of the diagnosis of ARVC, it 
FIGURE 3: A resting 12-lead ECG in a patient with ARVC
A: The ECG shows typical abnormalities: The QRS morphology is abnormal with a delayed 
second component, most notable in V1. This is an Epsilon wave, which occurs in the right 
precordial leads, and may be upright or inverted, as it is here.  Note also the inverted T waves 
in all the chest leads, which are abnormal if present beyond V1 after childhood. (The sinus 
bradycardia is due to beta-blockers.)
B: A sensitive measurement  in ARVC that may be positive even before Epsilon waves can be 
discerned, is the duration of the S wave upstroke >55ms. In this patient, the measurement 
from the nadir of the S wave to termination of the QRS or when the S wave upstroke reaches 
baseline is 70ms, which is abnormal.
A B
TABLE 2:  Points to Remember about ARVC
Symptoms  
Fainting episodes, especially with exercise
Episodes of transient or persistent palpitations; may be associated with lightheadedness
Diagnostic Clues    
Family History
Unexplained sudden death in young or middle aged family member(s)
ECG fi ndings
T-wave inversions beyond lead V1
Epsilon waves in leads V1-V3
Ventricular premature beats with left bundle branch confi guration
Abnormal electrical potentials in high-resolution (signal-averaged) ECG 
Echocardiography
Dilated RV with aneurysms
Treatment   
Antiarrhythmic medications
ICD
Radiofrequency ablation
Heart transplant
FIGURE 4: Right Ventricular angiographic features of ARVC
This RV angiogram would be best appreciated in “movie” mode as it shows hypokinesia of the 
entire anterior wall and apex. Other typical abnormalities can be noted here: along the 
anterior wall prominent trabeculations, which may have a “stack of coins” appearance, and 
localized aneurysms closer to the RV outfl ow region.
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has been shown that the sensitivity and specifi city of CMRI are directly 
related to the experience of the radiologist in the reading of ARVC 
cases.(11,12,19) Multidetector Cardiac CT has shown promise as an 
alternative imaging modality with the added benefi t of coronary 
anatomy evaluation.(13)
TREATMENT
Treatment of ARVC is directed toward preventing life-threatening 
ventricular arrhythmias. This is achieved by sports avoidance and a 
combination of anti-arrhythmic drugs, radiofrequency ablation and 
ICDs.(5,14,15,19) 
All forms of intense physical activity and endurance sport should be 
prohibited; competitive sport is also to be avoided. These activities 
are associated with an unacceptably high risk of death and avoidance 
has been shown to be associated with a reduction in SCD among 
participants.  An exercise test may be of benefi t in identifying individuals 
at risk for developing exercise-induced arrhythmias but, as it is unable 
to mimic the competitive sport situation with its probable associated 
catecholamine rise and sympathetic effects, its sensitivity is low.(16,22)
Beta-blockers are the most commonly used drugs. Alternative agents 
include sotalol and amiodarone. 
Radiofrequency ablation (RFA) may be used as the sole treatment 
modality in selected cases where the VT originates from a focal area 
amenable to ablation; however, it is mostly combined with anti-
arrhythmic agents or an ICD.  It is indicated particularly for drug failure 
and break-through arrhythmias or frequent ICD shock therapy. 
Although effective in the short term, RFA is not curative and is 
associated with a high recurrence of VT of 40% at 3 years, probably due 
to the progressive nature of the disease.(14)
Major risk factors for adverse prognosis are: young age, family history 
of juvenile sudden death, QRS dispersion ≥ 40 ms, T-wave inversion, 
left ventricular involvement, cardiac failure, ventricular tachycardia, 
syncope and previous cardiac arrest. Sports avoidance, ICDs and heart 
transplant (in severe heart failure) are life-saving interventions.(14,15,16,19
SA ARVC REGISTRY
International registries have been established in order to address issues 
relating to pathogenesis, prognosis and treatment. Much of our 
understanding of ARVC emanates from this.(5,6,7,9,11,12,14,19,20) To this end, 
the SA ARVC registry, under the steering of the Working Group on 
Registries of the Cardiac Arrhythmia Society of Southern Africa 
(CASSA) was established. The coordinating centre is based in the 
Cardiac Clinic, Groote Schuur Hospital, Cape Town. Ethics approval had 
been obtained from the Research Ethics Committee of the University 
of Cape Town Faculty of Health Sciences.
Prospective enrolment has taken place since January 2004. Physicians 
refer suspected cases to the registry coordinator. After the diagnosis 
has been confi rmed by the diagnostic panel, patients are invited, with 
consent, to partake in the registry. Written informed consent is obtained 
for blood samples for DNA analysis and for release to the registry and 
storage of any biopsy material obtained previously during diagnostic 
work-up by the treating physician. Additional written consent is obtained 
for any further investigations which may be performed to confi rm the 
diagnosis of ARVC, to determine the extent or severity of the disease 
or for prognostication purposes. 
The functional organization of the registry has been formalized (see the 
organogram in Figure 6). The registry has six major missions: DNA/
Tissue bank, epidemiology, risk assessment and evaluation of therapy, 
imaging, pathological diagnosis and diagnostic validation.
DNA / Tissue banking
Blood samples for DNA analysis are obtained from all confi rmed cases 
and family members to determine gene loci and to identify specifi c 
abnormal genes.
FIGURE 5: Cardiac Magnetic Resonance Imaging in ARVC
This MRI 4-chamber view of a patient with advanced ARVC shows some of the typical 
features: dilated right ventricle (RV), dilated right atrium (RA), multiple aneurysms of the RV 
free wall. The left ventricle (LV) is displaced posteriorly, in this patient, by the massive RV. 
The LV size is preserved.
RA
RV
LV
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This will enable genotype-phenotype correlation and facilitate family 
screening for identifi ed mutations. 
Epidemiology
The screening for and the detection of familial occurrence by means of 
ECG, SAECG, Holter 24-hour ECG recording, exercise stress test, 
echocardiography, CMRI and genetic screening of known mutations will 
expand the limited epidemiological database of this condition in 
southern Africa. The pathology reports of explanted hearts obtained at 
cardiac transplantation, will be reviewed for features consistent with 
ARVC. Anatomical and forensic pathologists across South Africa will be 
encouraged to forward identifi ed potential cases for review.  
Risk stratifi cation and evaluation of therapies
The main aim is to identify prognostic factors and evaluate long-term 
effi cacy of current pharmacological and non-drug therapy.  
Imaging
In addition to evaluating the diagnostic and prognostic value of existing 
imaging modalities and techniques, new MRI protocols, such as those 
utilizing cine Displacement Encoding with Stimulated Echoes (cine 
DENSE) for quantifying regional myocardial strain based on phase 
contrast images optimized for RV, are being developed using the registry 
patients to enhance earlier disease detection.
Pathology registry and tissue bank
A cardiac pathology registry has been set up to collect either heart 
specimens or endomyocardial biopsies. Protocols have been developed 
for processing and analysis of these specimens including immuno-
histochemistry, histochemistry, electron microscopy and myocyte 
culture. Insight will be gained into the etiopathogenesis of the disease 
and the diagnostic value of endomyocardial biopsy in the workup of 
suspected cases of ARVC.  
RESULTS AND REGISTRY DATA
To date, 80 confi rmed cases of ARVC, 70 being probands, have been 
enrolled in the registry of whom 54/80 (68%) were males. The median 
age at diagnosis was 27.5 years (range 11-74 years), 23/80 (29%) of 
whom were 20 years or younger.  ARVC has been diagnosed in all racial 
groups.
With regard to inheritance, 48/80 (60%) had either a family member 
with confi rmed ARVC or a history of SCD or sudden unexplained 
death.  LV involvement in ARVC, a measure of the extent of the disease, 
was present in 35/80 (44%), 4 of whom subsequently had heart 
transplants with another awaiting transplantation. Other relevant 
therapy data reveal that ICDs were implanted in 30/80 (38%). 
Assessment of potential risk factors shows that 40/80 (50%) participated 
in some form of organized sport; 4/80 (5%) were survivors of SCD 
which occurred whilst participating in sporting activity. 
 CASSA = The Cardiac Arrhythmia Society of Southern Africa
FIGURE 6: The Organogram of the SA ARVC Registry
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Follow-up data are available for 66/80 (83%) of whom 14/66 (21%) 
have died.
A novel genetic mutation in the plakophyllin gene was discovered in 
one family that presented with early progressive disease proceeding to 
cardiac transplantation in 2 siblings. 
DISCUSSION
This registry represents the largest cohort of ARVC patients from the 
African continent. The results confi rm the clustering of ARVC in families, 
the signifi cant role of endurance sport and the high mortality of 
ARVC.(4,6,16,19)
Despite the short existence of the registry and minimal fi nancial 
support, considerable strides have been made with respect to 
recruitment, data collection and novel fi ndings. In this regard it compares 
favourably with the output of other international registries.(20) 
There remains a call for cardiologists and physicians across South Africa 
to be vigilant in identifying affected individuals and to be diligent in 
referring all suspected or confi rmed cases of ARVC to the registry in 
order for it to achieve its goals.
Contact details for referral of confi rmed and suspected cases of ARVC: 
arvc.sa@uct.ac.za
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